Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Bernard Masquelier"'
Autor:
Christophe Rodriguez, Cathia Soulié, Anne-Geneviève Marcelin, Vincent Calvez, Diane Descamps, Charlotte Charpentier, Philippe Flandre, Patricia Recordon-Pinson, Pantxika Bellecave, Jean-Michel Pawlotsky, Bernard Masquelier, ANRS AC11 Study Group
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0127816 (2015)
Maraviroc is an HIV entry inhibitor that alters the conformation of CCR5 and is poorly efficient in patients infected by viruses that use CXCR4 as an entry coreceptor. The goal of this study was to assess the capacity of ultra-deep pyrosequencing (UD
Externí odkaz:
https://doaj.org/article/2db05178ea68403abfc1e3b7a0b4b20f
Autor:
Marie-Anne Vandenhende, Pantxika Bellecave, Patricia Recordon-Pinson, Sandrine Reigadas, Yannick Bidet, Mathias Bruyand, Fabrice Bonnet, Estibaliz Lazaro, Didier Neau, Hervé Fleury, François Dabis, Philippe Morlat, Bernard Masquelier
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e86771 (2014)
OBJECTIVES: Clinical relevance of low-frequency HIV-1 variants carrying drug resistance associated mutations (DRMs) is still unclear. We aimed to study the prevalence of low-frequency DRMs, detected by Ultra-Deep Sequencing (UDS) before antiretrovira
Externí odkaz:
https://doaj.org/article/e8a67978128345c8bc88af8677f54121
Autor:
Giota Touloumi, Nikos Pantazis, Marie-Laure Chaix, Heiner C Bucher, Robert Zangerle, Anne-Marte Bakken Kran, Rodolphe Thiebaut, Bernard Masquelier, Claudia Kucherer, Antonella d'Arminio Monforte, Laurence Meyer, Kholoud Porter, for CASCADE Collaboration in EuroCoord
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e71174 (2013)
We aimed to compare rates of virologic response and CD4 changes after combination antiretroviral (cART) initiation in individuals infected with B and specific non-B HIV subtypes.Using CASCADE data we analyzed HIV-RNA and CD4 counts for persons infect
Externí odkaz:
https://doaj.org/article/dbbff676238d46d7a24533d77b8f2e0b
Autor:
Sidonie Lambert-Niclot, Philippe Flandre, Marc-Antoine Valantin, Cathia Soulie, Slim Fourati, Marc Wirden, Sophie Sayon, Sophie Pakianather, Laurence Bocket, Bernard Masquelier, Georges Dos Santos, Christine Katlama, Vincent Calvez, Anne-Genevieve Marcelin
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e41390 (2012)
A higher proportion of intermittent viremia (to have a HIV-1 RNA viral load>50 copies/mL not confirmed) was reported in the boosted protease inhibitor monotherapy arm in some studies including MONOI trial, and that could have an impact on the repleni
Externí odkaz:
https://doaj.org/article/b2ae03f67d7f4660b07da8e9caaee1c2
Autor:
Sandrine Reigadas, Guerric Anies, Bernard Masquelier, Christina Calmels, Lieven J Stuyver, Vincent Parissi, Herve Fleury, Marie-Line Andreola
Publikováno v:
PLoS ONE, Vol 5, Iss 4, p e10311 (2010)
Resistance to HIV-1 integrase (IN) inhibitor raltegravir (RAL), is encoded by mutations in the IN region of the pol gene. The emergence of the N155H mutation was replaced by a pattern including the Y143R/C/H mutations in three patients with anti-HIV
Externí odkaz:
https://doaj.org/article/c6ac617748ef4c2897a83543ffe133ac
Autor:
Roger Paredes, B. Masquelier, Bernard Masquelier, Rolf Kaiser, A.M. Geretti, Klaus Jansen, A d'Arminio Monforte, Erika Castro, K.J. Metzner, Anna Schultze, Clare Booth, Rob Schuurman, F. Brun-Vezinet, Francesca Ceccherini-Silberstein, Roger D. Kouyos, Norbert H. Brockmeyer, F. Di Giallonardo, Martin P. Däumer, Huldrych F. Günthard, Karin J. Metzner, Françoise Brun-Vézinet, Marc Noguera-Julian, Günthard Hf, Anna Maria Geretti, F. Ceccherini-Silberstein, Susan C. Aitken, Hansjakob Furrer, Alessandro Cozzi-Lepri, Claudia Michalik, R. Schuurman, Pantxika Bellecave, A. Cozzi-Lepri
Publikováno v:
Clinical Microbiology and Infection. 22:191-200
Plasma drug-resistant minority human immunodeficiency virus type 1 variants (DRMVs) increase the risk of virological failure to first-line non-nucleoside reverse transcriptase inhibitor antiretroviral therapy (ART). The origin of DRMVs in ART-naive p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::666da0055660680675e937934ba42f65
https://doi.org/10.1016/j.cmi.2015.10.004
https://doi.org/10.1016/j.cmi.2015.10.004
Autor:
Virginie Ferré, Jacqueline Cottalorda, Anne-Geneviève Marcelin, Véronique Schneider, Laurence Morand-Joubert, Jacques Izopet, Diane Descamps, Lambert Assoumou, Coralie Pallier, Souhila Saidi, Bernard Masquelier, Marie-Laure Chaix, Annick Ruffault, Constance Delaugerre, Vincent Calvez, Sabine Yerly, Françoise Brun-Vézinet, Jean-Christophe Plantier, Gilles Peytavin, Brigitte Montes, Dominique Costagliola, Catherine Tamalet
Objectives: We studied gp41 mutations associated with failing enfuvirtide salvage therapy. Methods: This multicentre study involved patients with HIV-1 plasma viral load (pVL) > 5000 copies/mL after at least 3 months of uninterrupted enfuvirtide ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b4f25a4aace439ef05c74e2eaa0df0
http://doc.rero.ch/record/295629/files/dkn225.pdf
http://doc.rero.ch/record/295629/files/dkn225.pdf
Autor:
A. G. Marcelin, Charlotte Charpentier, Benoit Visseaux, Marc Wirden, Bernard Masquelier, Diane Descamps, Vincent Calvez, Cathia Soulié, Laurence Morand-Joubert
Publikováno v:
Journal of Global Antimicrobial Resistance. 2:103-106
To treat human immunodeficiency virus (HIV)-infected patients, international guidelines recommend the combination of two nucleos(t)ide reverse transcriptase inhibitors [N(t)RTIs] and a third agent [non-NRTI (NNRTI), boosted protease inhibitor (r/PI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0f3c1c407d2093969ab850beed7a853
https://doi.org/10.1016/j.jgar.2013.12.001
https://doi.org/10.1016/j.jgar.2013.12.001
Autor:
Bernard Masquelier, Vincent Calvez, Sidonie Lambert-Niclot, Cathia Soulié, Alexandre Storto, Anne-Geneviève Marcelin, Charlotte Charpentier, Philippe Flandre, Marc Wirden, D. B. Fofana, Diane Descamps, Laurence Morand-Joubert, Slim Fourati
Publikováno v:
Journal of Antimicrobial Chemotherapy; Vol 69
In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this study was to describe rilpivirine, tenofovir and emtricitabine resistance in HIV-1-infected patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63db3ab341cea836fb6caa42ded2d0e
https://doi.org/10.1093/jac/dkt463
https://doi.org/10.1093/jac/dkt463
Autor:
Slim Fourati, Philippe Flandre, Charlotte Charpentier, Vincent Calvez, Sidonie Lambert-Niclot, Benoit Visseaux, Bernard Masquelier, Diane Descamps, Marc Wirden, D. B. Fofana, Alexandre Storto, Anne-Geneviève Marcelin, Laurence Morand-Joubert, Cathia Soulié
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy; Vol 68
Journal of Antimicrobial Chemotherapy; Vol 68
OBJECTIVES The prevalence of rilpivirine, emtricitabine and tenofovir resistance-associated mutations (RAMs), described in vitro and in vivo, was determined in antiretroviral-naive patients. PATIENTS AND METHODS From 2008 to 2011, 1729 treatment-naiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ebd5f2159293e625a8002ce2062ec50